<DOC>
	<DOCNO>NCT01777334</DOCNO>
	<brief_summary>The purpose 24 week study evaluate spirometric lung function effect ( trough FEV1 ) Umeclidinium/Vilanterol 62.5/25 daily compare Tiotropium 18 mcg daily along safety assessment subject COPD .</brief_summary>
	<brief_title>The Purpose This Study Evaluate Spirometric Effect ( Trough FEV1 ) Umeclidinium/Vilanterol 62.5/25 mcg Once Daily Compared With Tiotriopium 18 mcg Once Daily Over 24-week Treatment Period Subjects With COPD .</brief_title>
	<detailed_description>This Phase IIIb multicenter , randomize , double-dummy , parallel group study evaluate efficacy safety UMEC/VI Inhalation Powder ( 62.5/25 mcg ) administer once-daily via novel dry powder inhaler ( DPI ) compare tiotropium ( 18 mcg ) administer once-daily via HandiHaler treatment period 24 week subject COPD . Eligible subject randomize 1:1 UMEC/VI Inhalation Powder ( 62.5/25 mcg ) , tiotropium ( 18 mcg ) 24 week . There total 10 study clinic visit conduct outpatient basis . Subjects meet eligibility criterion Screening ( Visit 1 ) complete 7- 10-day run-in period follow 24-week treatment period . Clinic visit Screening , Randomization ( Day 1 ) , Day 2 4 , 8 , 12 , 16 , 20 24 week , 1 day Week 24 visit ( Visit 1 Visit 10 , respectively ) . Additionally safety Follow-Up assessment conduct either phone call clinic visit require approximately 7 day end study treatment ( Visit 10 Early Withdrawal , applicable ) . The total duration subject participation , include Follow-Up approximately 26 week .</detailed_description>
	<mesh_term>Lung Diseases</mesh_term>
	<mesh_term>Pulmonary Disease , Chronic Obstructive</mesh_term>
	<mesh_term>Chronic Disease</mesh_term>
	<mesh_term>Tiotropium Bromide</mesh_term>
	<mesh_term>Muscarinic Antagonists</mesh_term>
	<criteria>Type subject : Outpatient . Informed Consent : A sign date write informed consent prior study participation . Age : Subjects 40 year age old Visit 1 . Gender : Male female subject . A female eligible enter participate study : Nonchild bear potential ( i.e . physiologically incapable become pregnant , include female postmenopausal surgically sterile ) . Surgically sterile female define documented hysterectomy and/or bilateral oophorectomy tubal ligation . Postmenopausal female define amenorrhoeic great 1 year appropriate clinical profile , e.g . age appropriate , &gt; 45 year , absence hormone replacement therapy . OR Child bear potential , negative pregnancy test screening , agree one follow acceptable contraceptive method use consistently correctly ( i.e . accordance approve product label instruction physician duration study screen followup contact ) : Abstinence Oral Contraceptive , either combined progestogen alone Injectable progestogen Implants levonorgestrel Estrogenic vaginal ring Percutaneous contraceptive patch Intrauterine device ( IUD ) intrauterine system ( IUS ) meet SOP effectiveness criterion state product label Male partner sterilization ( vasectomy documentation azoospermia ) prior female subject 's entry study , male sole partner subject . For definition , `` document '' refers outcome investigator's/designee 's medical examination subject review subject 's medical history study eligibility , obtain via verbal interview subject subject 's medical record . Double barrier method : condom occlusive cap ( diaphragm cervical/vault cap ) vaginal spermicidal agent ( foam/gel/film/cream/suppository ) COPD Diagnosis : An established clinical history COPD accordance definition American Thoracic Society/European Respiratory Society [ Celli , 2004 ] . Smoking History : Current former cigarette smoker history cigarette smoke &gt; =10 packyears [ number pack year = ( number cigarette per day / 20 ) x number year smoke ( e.g. , 20 cigarette per day 10 year , 10 cigarette per day 20 year ) ] . Previous smoker define stop smoke least 6 month prior Visit 1 . Note : Pipe and/or cigar use use calculate packyear history Severity Disease : A pre postalbuterol/salbutamol FEV1/FVC ratio &lt; 0.70 pre postalbuterol/salbutamol FEV1 FEV1 &lt; =70 % predict normal value calculate use NHANES III reference equation Visit 1 [ Hankinson , 1999 ; Hankinson , 2010 ] . Dyspnea : A score â‰¥2 Modified Medical Research Council Dyspnea Scale ( mMRC ) Visit 1 . Pregnancy : Women pregnant lactate plan become pregnant study . Asthma : A current diagnosis asthma . Other Respiratory Disorders : Known alpha 1 antitrypsin deficiency , active lung infection ( tuberculosis ) , lung cancer absolute exclusionary condition . A subject , opinion investigator , significant respiratory condition addition COPD exclude . Examples may include clinically significant bronchiectasis , pulmonary hypertension , sarcoidosis , interstitial lung disease . Other Diseases/Abnormalities : Subjects historical current evidence clinically significant cardiovascular , neurological , psychiatric , renal , hepatic , immunological , endocrine ( include uncontrolled diabetes thyroid disease ) hematological abnormality uncontrolled and/or previous history cancer remission &lt; 5 year prior Visit 1 ( localize carcinoma skin resect cure exclusionary ) . Significant defined disease , opinion investigator , would put safety subject risk participation , would affect efficacy safety analysis disease/condition exacerbate study . Contraindications : A history allergy hypersensitivity anticholinergic/muscarinic receptor antagonist , beta2agonist , lactose/milk protein magnesium stearate medical condition narrowangle glaucoma , prostatic hypertrophy bladder neck obstruction , opinion study physician contraindicates study participation use inhale anticholinergic . Hospitalization : Hospitalization COPD pneumonia within 12 week prior Visit 1 . Lung Resection : Subjects lung volume reduction surgery within 12 month prior Screening ( Visit 1 ) . 12Lead ECG : An abnormal significant ECG find 12lead ECG conduct Visit 1 , include presence pace rhythm 12lead electrocardiogram ( ECG ) cause underlying rhythm ECG obscure . Investigators provide ECG review conduct centralized independent cardiologist assist evaluation subject eligibility . Specific ECG finding preclude subject eligibility list Appendix 4 . The study investigator determine medical significance ECG abnormality list Appendix 4 . Medication Prior Spirometry : Unable withhold albuterol/salbutamol 4 hour period require prior spirometry test study visit . Use certain medication accord defined time interval prior Screening ( Visit 1 ) . Oxygen : Use longterm oxygen therapy ( LTOT ) describe oxygen therapy prescribe great 12 hour day . Asneeded oxygen use ( i.e. , &gt; =12 hour per day ) exclusionary . Nebulized Therapy : Regular use ( prescribe use every day , asneeded use ) shortacting bronchodilator ( e.g. , albuterol/salbutamol ) via nebulized therapy . Pulmonary Rehabilitation Program : Participation acute phase pulmonary rehabilitation program within 4 week prior Visit 1 . Subjects maintenance phase pulmonary rehabilitation program exclude . Drug Alcohol Abuse : A know suspected history alcohol drug abuse within 2 year prior Visit 1 . Affiliation Investigator Site : Is investigator , subinvestigator , study coordinator , employee participate investigator study site , immediate family member aforementioned involve study . Previous use study drug : Previous participation DB2113360 DB2113374 .</criteria>
	<gender>All</gender>
	<minimum_age>40 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>November 2016</verification_date>
</DOC>